Histomorphometric Analysis of Lumbar Vertebrae From Control and 5TGM1 Myeloma-Bearing Mice With or Without Ibandronate Treatment
| Treatment Group . | Percent Trabecular Bone Volume . | Cortical Bone Thickness (μm) . | Percent Marrow Replacement by Tumor . |
|---|---|---|---|
| Control + PBS | 18.1 ± 0.8 (n = 6) | 48.8 ± 1.4 (n = 6)† | None |
| Control + IBN | 21.0 ± 1.0 (n = 6) | 63.9 ± 3.4 (n = 6)* | None |
| Myeloma + PBS | 12.9 ± 1.2 (n = 6)*,† | 42.9 ± 2.5 (n = 4)† | 71.7 ± 12.2 (n = 6) |
| Myeloma + IBN | 21.3 ± 1.2 (n = 6) | 59.0 ± 2.9 (n = 5)* | 70.6 ± 4.9 (n = 6) |
| Treatment Group . | Percent Trabecular Bone Volume . | Cortical Bone Thickness (μm) . | Percent Marrow Replacement by Tumor . |
|---|---|---|---|
| Control + PBS | 18.1 ± 0.8 (n = 6) | 48.8 ± 1.4 (n = 6)† | None |
| Control + IBN | 21.0 ± 1.0 (n = 6) | 63.9 ± 3.4 (n = 6)* | None |
| Myeloma + PBS | 12.9 ± 1.2 (n = 6)*,† | 42.9 ± 2.5 (n = 4)† | 71.7 ± 12.2 (n = 6) |
| Myeloma + IBN | 21.3 ± 1.2 (n = 6) | 59.0 ± 2.9 (n = 5)* | 70.6 ± 4.9 (n = 6) |
The effect of ibandronate treatment (4 μg per mouse per day for 28 days) on percent trabecular bone volume, cortical bone thickness, and percent marrow replacement by tumor. Data are mean ± SEM. Each data point represents a mean calculated from measurements from at least three lumbar vertebrae for each animal.
Significantly different from control + PBS.
Significantly different from myeloma + ibandronate.